To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

NCT00844844 ·Status: COMPLETED ·Phase: PHASE2

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)

NCT00838513 ·Status: COMPLETED ·Phase: PHASE2

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

NCT01194973 ·Status: COMPLETED ·Phase: PHASE2

Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

NCT05876351 ·Status: COMPLETED ·Phase: PHASE3

E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

NCT01194804 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

NCT02614898 ·Status: TERMINATED

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

NCT07308574 ·Status: RECRUITING ·Phase: PHASE4

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT02949128 ·Status: COMPLETED ·Phase: PHASE3

A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea

NCT05405777 ·Status: COMPLETED

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

NCT00122304 ·Status: COMPLETED ·Phase: PHASE3

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

NCT00122330 ·Status: COMPLETED ·Phase: PHASE3

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT03131219 ·Status: COMPLETED ·Phase: PHASE3

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

NCT01522183 ·Status: RECRUITING

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

NCT05726916 ·Status: RECRUITING ·Phase: PHASE3

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT05795140 ·Status: RECRUITING ·Phase: PHASE3

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)

NCT04859608 ·Status: COMPLETED ·Phase: PHASE3

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

NCT05805202 ·Status: RECRUITING ·Phase: NA

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

NCT05684159 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00867932 ·Status: COMPLETED ·Phase: PHASE4

Complement Inhibition in aHUS Dialysis Patients

NCT02464891 ·Status: TERMINATED ·Phase: PHASE2

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

NCT01221181 ·Status: COMPLETED ·Phase: PHASE1

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03056040 ·Status: COMPLETED ·Phase: PHASE3

A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

NCT05337683 ·Status: COMPLETED